open access
Vol 56, No 3 (2022)
Invited Editorial
Submitted: 2022-06-22
Accepted: 2022-06-24
Published online: 2022-06-30
Get Citation
Multiple sclerosis and related disorders: where do we stand in 2022?
1
Affiliations- Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poland
open access
Vol 56, No 3 (2022)
INVITED EDITORIALS — LEADING TOPIC
Submitted: 2022-06-22
Accepted: 2022-06-24
Published online: 2022-06-30
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Multiple sclerosis and related disorders: where do we stand in 2022?
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Invited Editorial
Pages
197-200
Published online
2022-06-30
Page views
4367
Article views/downloads
598
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2022;56(3):197-200.
Authors
Alicja Kalinowska-Łyszczarz
References (36)- Global Economic Impact of Multiple Sclerosis. Multiple Sclerosis International Federation. : 2010.
- Kalinowska-Lyszczarz A, Tillema JM, Tobin WO, et al. Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Mult Scler. 2022; 28(3): 441–452.
- Sapko K, Jamroz-Wiśniewska A, Marciniec M, et al. Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. Neurol Neurochir Pol. 2020; 54(3): 252–258.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.
- Brownlee WJ, Swanton JK, Altmann DR, et al. Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria. J Neurol Neurosurg Psychiatry. 2015; 86(5): 584–585.
- Schwenkenbecher P, Wurster U, Konen FF, et al. Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. Front Neurol. 2019; 10: 188.
- Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016; 87(13): 1393–1399.
- Calabrese M, Gasperini C, Tortorella C, et al. RIREMS group (Rising Italian Researchers in Multiple Sclerosis). "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. Neurology. 2019; 92(22): e2527–e2537.
- Juryńczyk M, Jakuszyk P, Kurkowska-Jastrzębska I, et al. Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. Neurol Neurochir Pol. 2021 [Epub ahead of print].
- Rovira À, Wattjes MP, Tintoré M, et al. MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015; 11(8): 471–482.
- Sąsiadek M, Hartel M, Siger M, et al. Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. Neurol Neurochir Pol. 2020; 54(5): 410–415.
- Kalinowska-Lyszczarz A, Guo Y, Lucchinetti CF. Update on the Pathology of the Central Nervous System Inflammatory Demyelinating Diseases. Neurol Neurochir Pol. : 2022.
- Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, et al. Pathological findings in central nervous system demyelination associated with infliximab. Mult Scler. 2020; 26(9): 1124–1129.
- Pittock SJ, McClelland RL, Achenbach SJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry. 2005; 76(12): 1693–1697.
- Pittock SJ, Lucchinetti CF. The pathology of MS: new insights and potential clinical applications. Neurologist. 2007; 13(2): 45–56.
- Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008; 131(Pt 7): 1759–1775.
- Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011; 365(23): 2188–2197.
- Metz I, Weigand SD, Popescu BFG, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014; 75(5): 728–738.
- Tobin WO, Kalinowska-Lyszczarz A, Weigand SD, et al. Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Neurology. 2021; 97(19): e1906–e1913.
- Topkan TA, Sokmen O, Kocer B, et al. Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder. Neurol Neurochir Pol. 2022 [Epub ahead of print].
- Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–189.
- Vanderdonckt P, Aloisi F, Comi G, et al. Tissue donations for multiple sclerosis research: current state and suggestions for improvement. Brain Commun. 2022; 4(2): fcac094.
- Jasiak-Zatońska M, Pietrzak A, Wyciszkiewicz A, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022 [Epub ahead of print].
- Kalinowska-Lyszczarz A, Pawlak MA, Pietrzak A, et al. Distinct regional brain atrophy pattern in multiple sclerosis and neuropsychiatric systemic lupus erythematosus patients. Lupus. 2018; 27(10): 1624–1635.
- Kalinowska-Łyszczarz A, Pawlak MA, Pietrzak A, et al. Subcortical gray matter atrophy is associated with cognitive deficit in multiple sclerosis but not in systemic lupus erythematosus patients. Lupus. 2018; 27(4): 610–620.
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24(2): 96–120.
- Wiendl H, Gold R, Berger T, et al. ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021; 14: 17562864211039648.
- Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al. Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment. Neurol Neurochir Pol. 2020; 54(5): 384–398.
- Manouchehri N, Shirani A, Salinas VH, et al. Clinical trials in multiple sclerosis: past, present, and future. Neurol Neurochir Pol. 2022 [Epub ahead of print].
- Waldemar Brola, Monika Adamczyk-Sowa, Alina Kułakowska, Joanna Głażewska, Anna Smaga, Halina Bartosik-Psujek. Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland; Neurol Neurochir Pol. : 2022.
- Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019; 76(5): 536–541.
- Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021; 78(10): 1197–1204.
- Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022 [Epub ahead of print].
- Monika Adamczyk-Sowa, Maria Nowak-Kiczmer, Jerzy Jaroszewicz, Thomas Berger. Immunosenescence and multiple sclerosis. Neurol Neurochir Pol. : 2022.
- Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022; 375(6578): 296–301.
- Fleischer M, Schuh H, Bickmann NM, et al. Anti-EBNA1 IgG titre is not associated with fatigue in multiple sclerosis patients. Neurol Neurochir Pol. 2022 [Epub ahead of print].
